glp 1 patch prescription Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism Emerging Role of Myostatin Inhibitors

Knig M, Lorentzen R, Torgauten HM, Tran TT, Schikora-Rustad S, Vaage EB, et al

In females, L2-Cmu mAb treatment led to a slight, albeit significant reduction in red blood cells (RBCs), hemoglobin (Hb), hematocrit (Hct), white blood cells (WBCs), lymphocytes (Supplementary Table 2), and serum phosphorus (Supplementary Table 3), though most values, with the exception of WBCs, remained within the normal range, and were less severely affected than previously reported with Ganitumab in young CD1 mice 26

Louie, T

4 A relevant interaction is also observed between GLP-1R agonists and the gut microbiota, although the specific effects of GLP-1 receptor signaling on this axis remain only partially elucidated

doi: 10.3390/cells8080818 48 KomatsuNTakayanagiH